Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over
Technology appraisal guidance
Reference number: TA1077
Published:
Please note revised title for ID6221. In addition ID6451 will now run as a separate appraisal on the same timelines. Please see relevant topic webpage for further information